US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Pharmaceuticals Market Research Reports & Industry Analysis

  • Biopharmaceuticals (201)
  • Diseases & Conditions (4155)
  • Drug Delivery (179)
  • Therapeutic Area (6495)
  • Vaccines (609)
RSS Feeds

Pharmaceuticals Industry Research & Market Reports

< prev 1    3  4  5  6  7  8  9  10  
The US Market for Rx to OTC Switches, 7th Edition
2/2/2015 | published by: Kalorama Information
... expirations, increasing competitiveness with the pharmaceutical environment, brand re-invention, consumer demand, and cost containment strategies. The U.S. market for Rx-to-OTC Switches encompasses a wide variety of products that have been determined safe and effective as ...  |  read more...
USD 3,995
Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Metastatic Breast Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Metastatic Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Metastatic Melanoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Essential Thrombocythemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Essential Thrombocythemia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Insomnia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Insomnia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Insomnia. ...  |  read more...
USD 2,000
Irritable Bowel Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Irritable Bowel Syndrome. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Keratitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... the Keratitis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Keratitis. ...  |  read more...
USD 2,000
Keratoconjunctivitis sicca (Dry Eye)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Keratoconjunctivitis sicca (Dry Eye). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Kidney Transplantation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Kidney Transplantation. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Metastatic Nonseminomatous Testicular Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Metastatic Nonseminomatous Testicular Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Metastatic Ovarian Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Myelodysplastic Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Myelodysplastic Syndrome. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Myoclonic Seizures-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Myoclonic Seizures. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Nosocomial Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Nosocomial Infections. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Lower Respiratory Tract Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Lower Respiratory Tract Infections. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Lung Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Lupus Erythematosus-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Lupus Erythematosus. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Ocular Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Ocular Hypertension. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Moderate Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Moderate Pain. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Ocular Inflammation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Ocular Inflammation. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Multiple Myeloma (Kahler's Disease)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Multiple Myeloma (Kahler's Disease). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Multiple Sclerosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Multiple Sclerosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Onychomycosis (Tinea Unguium)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Onychomycosis (Tinea Unguium). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Musculoskeletal Pain-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Musculoskeletal Pain. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Open-Angle Glaucoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Open-Angle Glaucoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
< prev 1    3  4  5  6  7  8  9  10